MedPath
Found 104 clinical trials|View Analysis
Sort by:

Study on Recurrent Breast Cancer and Repeated Radiation Therapy

Not Applicable
Not yet recruiting
Conditions
Recurrent Breast Carcinoma
First Posted Date
2024-11-26
Last Posted Date
2024-11-26
Lead Sponsor
Turku University Hospital
Target Recruit Count
60
Registration Number
NCT06704659
Locations
🇫🇮

Helsinki University Hospital, Helsinki, Finland

🇫🇮

Turku University Hospital, Turku, Finland

Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial

Phase 2
Recruiting
Conditions
Recurrent Breast Carcinoma
Ipsilateral Recurrence
First Posted Date
2024-10-15
Last Posted Date
2024-12-11
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
25
Registration Number
NCT06640881
Locations
🇳🇱

Amsterdam UMC / VU Medical Centre, Amsterdam, Netherlands

Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1
Not yet recruiting
Conditions
Anatomic Stage I Breast Cancer AJCC V8
Anatomic Stage IA Breast Cancer AJCC V8
Anatomic Stage IB Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage IIB Breast Cancer AJCC V8
Anatomic Stage IIA Breast Cancer AJCC V8
Metastatic Triple-Negative Breast Carcinoma
Prognostic Stage IA Breast Cancer AJCC V8
Prognostic Stage IB Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8
Interventions
First Posted Date
2024-03-21
Last Posted Date
2024-11-05
Lead Sponsor
Emory University
Target Recruit Count
18
Registration Number
NCT06324240
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Recruiting
Conditions
Metastatic Breast Carcinoma
Recurrent Breast Carcinoma
Breast Carcinoma
Interventions
Other: Non-Interventional Study
First Posted Date
2024-01-23
Last Posted Date
2024-01-23
Lead Sponsor
Mayo Clinic
Target Recruit Count
5000
Registration Number
NCT06217874
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

SMMART Adaptive Clinical Treatment (ACT) Trial

Early Phase 1
Withdrawn
Conditions
Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Prostate Carcinoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Breast Carcinoma
Stage IV Ovarian Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Interventions
Drug: Alectinib
Drug: Alpelisib
Drug: Anastrozole
Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Drug: Carboplatin
Drug: Cobimetinib
Drug: Entrectinib
Drug: Eribulin
Drug: Fulvestrant
Biological: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Drug: Irinotecan
Drug: Letrozole
Drug: Nab-paclitaxel
Drug: Niraparib
Drug: Olaparib
Drug: Paclitaxel
Drug: Palbociclib
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab
Biological: Trastuzumab Emtansine
Drug: Vemurafenib
Drug: Vinorelbine
Drug: Vismodegib
First Posted Date
2022-02-14
Last Posted Date
2024-01-23
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT05238831

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Phase 1
Recruiting
Conditions
Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Locally Advanced Cutaneous Melanoma
Metastatic Acral Lentiginous Melanoma
Metastatic Conjunctival Melanoma
Metastatic Cutaneous Melanoma
Metastatic HER2-Negative Breast Carcinoma
Metastatic Mucosal Melanoma
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
Biological: Neoantigen Peptide Vaccine
Biological: Nivolumab
Drug: Poly ICLC
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
First Posted Date
2021-10-28
Last Posted Date
2024-10-01
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT05098210
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase 1
Terminated
Conditions
Breast Inflammatory Carcinoma
Recurrent Breast Inflammatory Carcinoma
Stage IV Breast Inflammatory Carcinoma
Interventions
First Posted Date
2021-09-10
Last Posted Date
2024-10-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
25
Registration Number
NCT05041101
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Phase 2
Active, not recruiting
Conditions
Estrogen Receptor Positive
Primary or Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
Interventions
Drug: F-18 16 Alpha-Fluoroestradiol
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Drug: Fludeoxyglucose F-18
Other: Laboratory Biomarker Analysis
First Posted Date
2020-12-31
Last Posted Date
2024-10-21
Lead Sponsor
University of Washington
Target Recruit Count
2
Registration Number
NCT04692103
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2
Recruiting
Conditions
Anatomic Stage III Breast Cancer AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Castration-Resistant Prostate Carcinoma
Locally Advanced Breast Carcinoma
HER2-Positive Breast Carcinoma
Locally Advanced Gastric Carcinoma
Locally Advanced Malignant Solid Neoplasm
Locally Advanced Ovarian Carcinoma
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Talazoparib
First Posted Date
2020-09-16
Last Posted Date
2024-12-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
36
Registration Number
NCT04550494
Locations
🇺🇸

University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States

🇺🇸

National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 1 locations

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Phase 2
Not yet recruiting
Conditions
Anatomic Stage IV Breast Cancer AJCC V8
Metastatic Breast Carcinoma
Recurrent Breast Carcinoma
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Radiation: Gallium Ga 68-DOTATATE
Drug: Lutetium Lu 177 Dotatate
Procedure: Positron Emission Tomography
First Posted Date
2020-08-27
Last Posted Date
2024-12-20
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
10
Registration Number
NCT04529044
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath